Apogee Therapeutics, Inc. (APGE) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは Michael Thomas Henderson.
APGE を有する IPO日 2023-07-14, 196 名の正社員, に上場 NASDAQ Global Market, 時価総額 $4.95B.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
